Enanta Pharmaceuticals, Inc. (ENTA)

Revenue by Segment

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016
Biotechnology	65.32M	67.64M	79.20M	86.16M	97.07M
Biotechnology Growth	-3.42%	-14.61%	-8.07%	-11.24%	-20.74%
Total	65.32M	67.64M	79.20M	86.16M	97.07M
Total Growth	-3.42%	-14.61%	-8.07%	-11.24%	-20.74%

Revenue by Geography

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016
United States	65.32M	67.64M	79.20M	86.16M	97.07M
United States Growth	-3.42%	-14.61%	-8.07%	-11.24%	-20.74%
Total	65.32M	67.64M	79.20M	86.16M	97.07M
Total Growth	-3.42%	-14.61%	-8.07%	-11.24%	-20.74%

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 23, 2026

Data Sources Report a data error